Zoetis Inc. is engaged in the discovery, development, manufacturing, and commercialization of animal health medicines, vaccines, and diagnostic products globally. Its customer base includes veterinarians, livestock producers, and retail outlets, with revenue derived from various segments including vaccines (approximately 30%), anti-infectives (25%), parasiticides (20%), and other pharmaceutical products (25%). The company also offers diagnostic testing and non-pharmaceutical products. Factors supporting its endurance include a growing global demand for animal health products and a diverse product portfolio, while potential limitations could arise from regulatory challenges and competition from generic products.
—
Zoetis Inc. is engaged in the discovery, development, manufacturing, and commercialization of animal health medicines, vaccines, and diagnostic products globally. Its customer base includes veterinarians, livestock producers, and retail outlets, with revenue derived from various segments including vaccines (approximately 30%), anti-infectives (25%), parasiticides (20%), and other pharmaceutical products (25%). The company also offers diagnostic testing and non-pharmaceutical products. Factors supporting its endurance include a growing global demand for animal health products and a diverse product portfolio, while potential limitations could arise from regulatory challenges and competition from generic products.
—
Daily adjusted close
Zoetis Inc. is engaged in the discovery, development, manufacturing, and commercialization of animal health medicines, vaccines, and diagnostic products globally. Its customer base includes veterinarians, livestock producers, and retail outlets, with revenue derived from various segments including vaccines (approximately 30%), anti-infectives (25%), parasiticides (20%), and other pharmaceutical products (25%). The company also offers diagnostic testing and non-pharmaceutical products. Factors supporting its endurance include a growing global demand for animal health products and a diverse product portfolio, while potential limitations could arise from regulatory challenges and competition from generic products.